Build the AI-native twin of your organisation.
AI is a culture, and a Twin brings it in department by department: built beside your team, on the same work, proven on your own numbers.
Your knowledge, your experts and AI agents in one department. Every fact traced to its source, every decision with the people who answer for it.
The first company Twin is Pharma. Its first operating department is Business Development & Licensing.
The first Twin
Experience becomes
company knowledge.
The history is our foundation.
The Twin is its next capability.
MondoBiotech brought science, entrepreneurship and specialist partners together around rare diseases. MondoTwin connects that experience with structured evidence, agents and reviewed work.
The first Twin revives MondoBiotech’s rare-disease search-and-license model as an AI-native company. Its first operating department is Business Development & Licensing.
The Twin in practice
Every answer,
traced to its source.
Five example questions. For each, the records the Twin’s agents consult, what each returns, and the answer with its primary sources.
Has adding sildenafil to nintedanib been tried in idiopathic pulmonary fibrosis, and is the pair safe to give together?
- screen_ddisildenafil, nintedanib · chronic exposuremonitor · medium confidence · 2 curated records · no shared enzyme · haematologic flag on both
- search_clinical_studiessildenafil nintedanib · idiopathic pulmonary fibrosisINSTAGE, NCT02802345 · phase 3 · completed · 274 patients · negative result
- get_clinical_studyNCT02802345arms, eligibility, endpoints, registry results, 8 publications
- check_fdc_feasibilitysildenafil, nintedanibsingle tablet · moderate · oral · half-lives 4 h and 9.5 h
It has been tried, and it did not help. INSTAGE, Boehringer Ingelheim’s 24-week phase 3, randomised 274 patients with IPF and advanced impairment (DLCO ≤ 35 % predicted) to nintedanib with sildenafil or nintedanib with placebo, in 13 countries. On the primary endpoint, the change in SGRQ total score at week 12, the adjusted mean difference was −0.52 (95 % CI −3.33 to 2.30, p = 0.72). Dyspnoea moved no differently either.
- Registry
- NCT02802345 · EudraCT 2015-002619-14
- Design
- Randomised, double-blind, nintedanib + sildenafil against nintedanib + placebo
- Population
- IPF, 40 years and older, DLCO ≤ 35 % predicted
- Primary endpoint
- SGRQ total score, change at week 12
- Result
- −0.77 against −1.28; difference −0.52, p = 0.72
- Publications
- 8 on PubMed
Given together: monitor. DrugBank records that sildenafil can raise the serum concentration of nintedanib. The two share no enzyme where one is a perpetrator and the other a substrate. Both carry a weak haematologic flag on their labels. Renal effects were assessed for nintedanib only, cardiac rhythm and sedation for sildenafil only.
One product is possible. Both are oral. Half-lives differ 2.4 times (4 h against 9.5 h), so a shared schedule needs a modified-release form of sildenafil. Formulation difficulty: moderate.
SourcesNCT02802345EudraCT 2015-002619-14DrugBank DB00203DrugBank DB09079OnSIDESDILIrank
Example for research use. Medical decisions belong with a physician.
The technology
Make your company
understandable to intelligence.
Ontology. Agents.
Company OS.
One connected foundation for its knowledge, tools, work and decisions.
The technology combines ontology, agents and a Company OS. Models can change while the company knowledge and learning remain connected.
Origin
A Start-up company
of ETH Zurich.
MondoTwin is an ETH Start-up, founded by Francesco Cavalli, researcher at the ETH Agentic Systems Lab. The company begins with pharma business development and grows department by department.
The method, applied elsewhere
The next life
of your company.
MondoTwin Tech builds from your starting point: an idea, a company’s history, an AI transformation or an ambition to scale. Define a useful first function. Teach the Twin. Integrate what proves valuable.
- 01
An idea to build.
Define the model, test its assumptions and build the first useful capability.
Start here - 02
A history to renew.
Start with the available knowledge, experience and records of a company that has closed.
Start here - 03
A company to transform.
Teach the Twin the work, configure its tools and integrate useful AI capabilities.
Start here - 04
A business to scale.
Build on what works. Extend proven processes and company knowledge into the next stage of growth.
Start here
Rare.
No longer neglected.
A long rare-disease mission. A new way to carry it forward.